Fazamorexant clinical trials
Also written YZJ-1139.
How each study uses fazamorexant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (9)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fazamorexant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate TabletsCompletedPhase 1Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06680531Written as YZJ-1139 tablets
- Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal ImpairmentCompletedPhase 1Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06671444Written as YZJ-1139
- A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy SubjectsCompletedPhase 1Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06671470Written as YZJ-1139 tablets
- Safety and Efficacy Study of YZJ-1139 in Insomnia DisorderCompletedPhase 3Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT05525637Written as YZJ-1139 20mg
- Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia DisorderCompletedPhase 3Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06975514Written as YZJ-1139
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy ParticipantsCompletedPhase 1Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06673927Written as YZJ-1139
- PK/PD Study of YZJ-1139CompletedPhase 1Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06685341Written as YZJ-1139
- Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia DisorderCompletedPhase 2Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06680505Written as YZJ-1139 10mg
- Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic ImpairmentCompletedPhase 1Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06671509Written as YZJ-1139
Codes
What other systems call fazamorexant · ClinicalTrials.gg INT017288
- UNII (FDA) MDH4D7M594FAZAMOREXANTConfirmed FDA, Wikidata
- Wikidata Q131177082fazamorexantConfirmed FDA, Wikidata
- NCI Thesaurus C199047FazamorexantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MDH4D7M594 | FAZAMOREXANT | Confirmed FDA, Wikidata |
| Wikidata | Q131177082 | fazamorexant | Confirmed FDA, Wikidata |
| NCI Thesaurus | C199047 | Fazamorexant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.